|

Sasanlimab Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: PF-06801591

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Stephanie Berg1
  • Pfizer1
  • National Cancer Institute (NCI)1

Indications

  • Cancer3
  • Advanced Clear Cell Renal Cell Carcinoma1
  • Metastatic Renal Cancer1
  • Papillary Renal Cell Carcinoma (Prcc)1
  • Advanced Clear Cell Renal Carcinoma (Ccrcc)1

Birmingham, Alabama1 trial

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

University of Alabama at Birmingham

Phase 1

Bethesda, Maryland1 trial

Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

National Institutes of Health Clinical Center

Phase 1/2

Boston, Massachusetts1 trial

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Brigham and Women's Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.